Journal Logo

Research Article: Clinical Trial/Experimental Study

A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG

Wang, Xiaojuan MD; Chen, Xiaoyang MD; Zhu, Chaoxia MD; Ma, Haichang MD; Wang, Fang MD; Qin, Lingzhi MD; Li, Wei PhD*

Section Editor(s): Yi., Kou

Author Information
doi: 10.1097/MD.0000000000013100
  • Open

Abstract

1 Introduction

Neuromyelitis optica spectrum disorders (NMOSD; also known as Devic's disease) is a rare but serious autoimmune-related demyelinating disease of the central nervous system (CNS) that mainly affects the optic nerves and spinal cord with high recurrence rate, and usually misdiagnosed as multiple sclerosis (MS) or acute disseminated encephalomyelitis (ADEM).[1,2] This disease has been described for a century or more before the discovery of the highly specific autoantigen of immunoglobulin G (IgG) antibodies targeting aquaporin-4 (AQP4) which regulates water homeostasis.[3–5] It has a striking female preponderance of 9:1, of which 80% to 90% have relapsing course, and 10% to 20% patients have monophasic course.[3–5]

Previous studies have demonstrated the association between NMOSD and the presence of AQP4-IgG, but the possible different clinical features in patients with seropositive or seronegative NMOSD are not well defined. In this study, we divided patients with NMOSD into AQP4-IgG positive (+) and AQP4-IgG negative (−) groups by the serologic test and made a comparative analysis of them to improve the clinical recognition for physicians.

2 Methods

2.1 Patients

This study was carried out in People's Hospital of Zhengzhou University. We retrospectively reviewed the electronic medical records of 95 patients from September 2015 to November 2016. All patients met the diagnosis of NMOSD according to the international consensus diagnostic criteria described as below. Patients were divided into AQP4-IgG (+) and AQP4-IgG (−) groups. To compare the disorders of the 2 groups, demographic data, clinical information, laboratory studies, image findings, drug treatment, and clinical efficacy, and the score of Expanded Disability Status Scale (EDSS) were carefully reviewed by 3 experienced investigators to ensure accurate diagnosis.

2.2 Laboratory test

Serology tests were carried out before treatment, including the detection of AQP4-IgG antibody, thyroid hormone determinations, extractable nuclear antigen (ENA) autoantibodies or more.

2.3 Magnetic resonance imaging (MRI)

Brain and spinal cord MRI were performed using a uniform protocol, including T1-weighted images, T2-weighted images, sagital T1-weighted, and fluid-attenuated inversion recovery (FLAIR) images.

2.4 Inclusion/exclusion criteria for NMOSD

Patients must meet the diagnosis of NMOSD according to the international consensus diagnostic criteria.[6] Patients with incomplete clinical data, uncertain diagnosis, critical illness, mortality, or missing follow-up data were excluded.

2.5 Statistics

All data were analyzed using IBM SPSS Statistics Base 22.0. Categorical data were compared by the Chi-square test. The Mann–Whitney U test and t test analysis were used when appropriate. Quantitative data were expressed using median (range) or mean ± standard deviation (SD). Using Shapiro–Wilk test to verify its normal distribution, if passing, statistical significance was considered as P <.05.

3 Results

3.1 Demographic characteristics of the patients

Of the 95 patients who were initially diagnosed with NMOSD, 28 patients were later excluded. Among the 67 inclusions, 49 (73.1%, male/female: 3/46, mean age: 40.5 ± 16.7) are seropositive, and 18 (26.9%, male/female: 8/10, mean age: 38.5 ± 18.6) are seronegative (Table 1). There is no significant difference in age between the AQP4-IgG (+) patients and the AQP4-IgG (−) patients (P = .68 >.05) (Table 1).

Table 1
Table 1:
A comparison between seropositive and seropositive patients.

3.2 Clinical presentations

Among the 67 inclusions, patients present with optic neuritis (ON)[n = 34; AQP4-IgG (+)/(−): 31/3], isolated myelitis [n = 18; AQP4-IgG (+)/(−): 13/ 5], co-occurrence of ON and myelitis [n = 15; AQP4-IgG (+)/(−): 5/10]. Other initial symptoms include extremity weakness (n = 21), backache (n = 5), neck pain (n = 2), upper limb pain (n = 1), dizziness (n = 3), hiccup (n = 1), and diplopia (n = 2). In addition, nonspecific symptoms including dysphagia, ataxia and autonomic dysfunction were also found in several patients. Although it seems that motor symptoms were more common in the AQP4- IgG (−) group, there was no significant difference in onset of optic neuritis between them (Table 1).

3.3 MRI findings

Of the 67 patients [AQP4-IgG (+)/(−): 49/18], the MRI abnormals signals in AQP4(+), including 31 ON, 13 Myelitis, 5 ON and myelitis, 6 brain abnormals, 43 spinal cord abnormals (cervical cord, 27; thoracic cord, 16), and AQP4 (−): 3 ON, 5 Myelitis, 10 ON and myelitis, 3 brain abnormals, 18 spinal cord abnormals (cervical cord, 10; thoracic cord, 8). The intramedullary segment in AQP4-IgG (+) group was 5.30 ± 5.96 and was 5.28 ± 3.63 in AQP4-IgG (−) group. There was no statistically significant difference in MRI findings between the 2 groups (Table 1). The characteristic MRI manifestation in the AQP4-IgG(+) patients showed in Figure 1. The MRI manifestation in the AQP4- IgG (−) patients showed in Figure 2.

Figure 1
Figure 1:
The characteristic MRI manifestation in the AQP4-IgG(+) patients. T2-flair imagings showed the hyperintense beside the bilateral lateral ventricles (A) and the basal ganglia (B). T2-weighted brain MRI revealed the hyperintense in the the frontal lobe and the occipital lobe (C). Axial T2-weighted spinal cord MRI showed hyperintense in the cervical cord (D). AQP4-IgG = immunoglobulin G (IgG) antibodies targeting aquaporin-4, MRI = magnetic resonance imaging.
Figure 2
Figure 2:
The MRI manifestation in the AQP4-IgG(−) patients. T2-flair imagings showed the hyperintense in the brain stem (A). T2-weighted brain MRI revealed hyperintense in temporal lobe, parietal lobe and corpus callosum (B). Axial T2-weighted spinal cord MRI showed hyperintense in cervical cord and thoracic cord (C,D). AQP4-IgG = immunoglobulin G (IgG) antibodies targeting aquaporin-4, MRI = magnetic resonance imaging.

3.4 Baseline rates of comorbidities in NMOSD

18 cases were complicated with suspicious autoimmune diseases, including autoimmune thyroid disease (n = 6), sjogren syndrome (n = 4), rheumatoid arthritis (n = 4), systemic lupus erythematosus (n = 1), myasthenia gravis (n = 1), or abnormal autoantibodies without clinical features (n = 2). Compared with the AQP4-IgG-(−) group, the rate of co-existing autoimmune disorders was higher in the AQP4-IgG-(+) group (Table 1).

3.5 Treatment and outcome

66 cases were treated with methylprednisolone boli (500 mg QD × 3). After the therapy, the EDSS score of AQP4-IgG (+) group was 2.2 ± 1.3 and the AQP4-IgG (−) group was 1.6 ± 0.6, the difference was statistically significant (P <.05). 1 case was treated with nutrients with no improvement. The median duration of the 2 groups were 3.1 ± 3.6 years and 1.2 ± 2.9 years, respectively, which have significant difference (P = .04). The rate of AQP4-IgG (+) in the monophasic and recrudescent course patients was 28.6% and 71.4%, respectively, the difference is statistically significant (Table 1).

4 Discussion

NMOSD is an inflammatory, demyelinating syndrome of the CNS with the discrete, relapsing characters. Moreover, NMO-IgG, an autoantibody, especially attacks the AQP4 expression zone, especially the surrounding ventricular, which may induce corresponding clinical manifestations, such as ON or myelitis.[7–9] Population-based studies have described that 0.05 to 0.4 per 100,000 patients are AQP4-IgG (+), and this accounts for half of the clinical diagnosis of people with NMOSD.[10,11] An extensive literature showed that NMOSD may occur in any age, and in both sexes, but it has a postpubertal female preponderance.[1,12] Patients with co-existing autoimmune disorders may strengthen confidence about an NMOSD diagnosis. Since NMOSD has a high recurrence rate, disability rate, and disease burden and there may exist clinical differences between seropositive and seronegative patients, it is important to have a correct recognition.

We compared the clinical features of patients with AQP4-IgG (+) (n = 49, 73.1%) and AQP4-IgG (−) (n = 18, 26.9%) who had a clinical diagnosis of NMOSD.[6] Our study results suggest that patients with seropositive antibody tended to have a postpubertal female preponderance, single part involvement (ON or myelitis), autoimmune disorders coexistence, longer duration of symptoms, poor prognosis and polyphasic course. Statistical analysis showed that these differences between the 2 groups were significant (P <.05), but there was no difference in onset age and MRI lesions between the 2 groups (P >.05).

However, this study has several limitations as follows. First, we used indirect immunofluorescence to detect only AQP4-IgG antibody without other methods and antibodies. Second, there is a lack of within-group comparison in this study, including ages and clinical sympotoms. Third, this study did not compare NMOSD with other demyelinating disease of CNS, such as MS and ADEM. Additionally, this study may have some limitation such as small sample sizes and short-term follow-up.

Compared with AQP4-IgG (+) group, patients with AQP4-IgG (−) are likely to have a better prognosis and a favorable monophasic course. This reveals that AQP4 antibody not only can distinguish NMOSD from other diseases, but also may help to predict the patients who are at risk of recurrent, and could guide decisions regarding diagnostic and therapeutic strategies.

Acknowledgments

The authors thank all the patients for their participation in this study.

Author contributions

Conceptualization: Xiaojuan Wang.

Data curation: Xiaojuan Wang, Xiaoyang Chen.

Formal analysis: Xiaojuan Wang, Chaoxia Zhu, Haichang Ma, Fang Wang, Lingzhi Qin.

Investigation: Xiaojuan Wang, Xiaoyang Chen.

Methodology: Xiaojuan Wang, Wei Li, Xiaoyang Chen.

Supervision: Wei Li.

Validation: Xiaojuan Wang.

Writing – original draft: Xiaojuan Wang.

Writing – review & editing: Xiaojuan Wang.

References

[1]. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–15.
[2]. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009;66:1134–8.
[3]. Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003;4:991–1001.
[4]. Devic E. Myélite subaiguë compliquée de névrite optique. Bull Méd 1894;8:1033–4.
[5]. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–12.
[6]. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89.
[7]. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964–8.
[8]. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390–6.
[9]. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010;16:1229–36.
[10]. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 2015;21:845–53.
[11]. Waters PJ, Mckeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665.
[12]. Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–14.
Keywords:

AQP4-IgG; clinical features; neuromyelitis optica spectrum disorders

Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.